St. Jude at the 2017 IDF Annual Conference

June 15-17 in Anaheim, California

St. Jude Children’s Research Hospital campus

St. Jude Children’s Research Hospital is proud to be a participant in the Immune Deficiency Foundation Annual Conference. Please stop by Booth 217 in the Exhibit Hall to learn more about treatment, research and gene therapy clinical trials for immunodeficiency diseases.

SCID and SCID Variant Symposium

Hear St. Jude researchers Brian Sorrentino, MD, and Ewelina Mamcarz, MD, discuss advances in clinical research for Severe Combined Immunodeficiency (SCID).

Gene Therapy for Immunodeficiency Diseases

Read about innovative gene therapy approaches at St. Jude for patients with immune disorders and other conditions.

What is gene therapy?

Early Success for Lentiviral X-SCID Gene Therapy

In 2016, early, promising results were published from an X-linked SCID gene therapy trial at the National Institute of Allergy and Infectious Diseases (NIAID), using an innovative vector developed at St. Jude and NIAID and manufactured at a GMP facility on the St. Jude campus.

Read the full article >

Ongoing X-Linked SCID Clinical Trial

St. Jude is now enrolling infants up to age 2 with X-linked SCID for a gene therapy clinical trial.

View the study summary and eligibility requirements >

SCID Team at St. Jude

SCID Team at St. Jude

Brian Sorrentino, MD; Jay Lieberman, MD; Mike Meagher, PhD; Ewelina Mamcarz, MD